NVUS - Novus Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.75
-0.04 (-1.18%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close3.79
Open3.80
Bid3.67 x 700
Ask4.14 x 100
Day's Range3.75 - 3.85
52 Week Range3.42 - 9.09
Volume3,057
Avg. Volume8,809
Market Cap26.57M
Beta0.83
PE Ratio (TTM)N/A
EPS (TTM)-2.51
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Trade prices are not sourced from all markets
  • Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)?
    Simply Wall St.18 days ago

    Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)?

    Novus Therapeutics Inc (NASDAQ:NVUS), a USD$29.55M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...

  • PR Newswire2 months ago

    Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference

    IRVINE, Calif. , Nov. 21, 2017 /PRNewswire/ -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a development stage specialty pharmaceutical company focused on the development of products for disorders of the ...

  • Who Are The Largest Shareholders In Novus Therapeutics Inc (NVUS)?
    Simply Wall St.2 months ago

    Who Are The Largest Shareholders In Novus Therapeutics Inc (NVUS)?

    I am going to take a deep dive into Novus Therapeutics Inc’s (NASDAQ:NVUS) most recent ownership structure, not a frequent subject of discussion among individual investors. The impact of aRead More...

  • PR Newswire2 months ago

    Novus Therapeutics Reports Third Quarter 2017 Results

    IRVINE, Calif. , Nov. 8, 2017 /PRNewswire/ -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a development stage specialty pharmaceutical company focused on the development of products for disorders of the ear, ...

  • PR Newswire3 months ago

    Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President

    IRVINE, Calif., Nov. 6, 2017 /PRNewswire/ -- Novus Therapeutics, Inc. (NVUS), a development stage specialty pharmaceutical company focused on the development of products for disorders of the ear, nose, and throat (ENT), today announced that Catherine Turkel, Pharm.D., Ph.D. has been promoted to President.  Dr. Turkel joined the company in November 2015 as Senior Vice President of Clinical Research and Development and Chief Development Officer, with responsibility for U.S. research and development functions.  In this expanded role, Dr. Turkel will now be responsible global research and development as well as commercial strategy and development.

  • What’s The Outlook For Loss-Making Novus Therapeutics Inc (NVUS)?
    Simply Wall St.4 months ago

    What’s The Outlook For Loss-Making Novus Therapeutics Inc (NVUS)?

    Novus Therapeutics Inc (NASDAQ:NVUS) continues its loss-making streak, announcing a -$6.28M earnings for its latest financial year ending. Cash is crucial to run a business, and if a company burnsRead More...

  • PR Newswire5 months ago

    Novus Therapeutics Reports Second Quarter 2017 Results

    IRVINE, Calif. , Aug. 9, 2017 /PRNewswire/ -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a development stage specialty pharmaceutical company focused on the development of products for disorders of the ear, ...

  • PR Newswire6 months ago

    Novus Therapeutics Announces Change in Management

    IRVINE, Calif., July 10, 2017 /PRNewswire/ -- Novus Therapeutics, Inc. (NVUS), a pharmaceutical company focusing on the development of ear, nose, and throat (ENT) products, today announced that Jon Kuwahara has joined the company as Senior Vice President of Finance and Administration.  He succeeds Christine G. Ocampo who will continue to be engaged with the company as a consultant into 2018.

  • PR Newswire7 months ago

    Novus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    The grant was made as an inducement that was a material component of the new employee's compensation and subsequent acceptance of employment with the Company and was granted as an employment inducement award pursuant to Nasdaq Listing Rule 5635(c)(4) approved by the Company's Compensation Committee.